Report cover image

Global Biologics for Severe Asthma Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 189 Pages
SKU # APRC20278180

Description

Summary

According to APO Research, The global Biologics for Severe Asthma market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Biologics for Severe Asthma is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Biologics for Severe Asthma is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Biologics for Severe Asthma is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Biologics for Severe Asthma is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Biologics for Severe Asthma include Teva Pharmaceuticals, Sanofi, Novartis, Roche, Regeneron Pharmaceuticals, GSK, AstraZeneca and Amgen, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Biologics for Severe Asthma, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Biologics for Severe Asthma, also provides the sales of main regions and countries. Of the upcoming market potential for Biologics for Severe Asthma, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Biologics for Severe Asthma sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Biologics for Severe Asthma market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Biologics for Severe Asthma sales, projected growth trends, production technology, application and end-user industry.

Biologics for Severe Asthma Segment by Company

Teva Pharmaceuticals
Sanofi
Novartis
Roche
Regeneron Pharmaceuticals
GSK
AstraZeneca
Amgen
Biologics for Severe Asthma Segment by Type

Omalizumab
Benralizumab
Dupirumab
Mepolizumab
Reslizumab
Tezepelumab-ekko
Biologics for Severe Asthma Segment by Application

Clinic
Hospital
Other
Biologics for Severe Asthma Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics for Severe Asthma market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologics for Severe Asthma and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics for Severe Asthma.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Biologics for Severe Asthma market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biologics for Severe Asthma manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Biologics for Severe Asthma in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Biologics for Severe Asthma in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

189 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Biologics for Severe Asthma Market Size, 2020 VS 2024 VS 2031
1.3 Global Biologics for Severe Asthma Market Size Estimates and Forecasts (2020-2031)
1.4 Global Biologics for Severe Asthma Sales Estimates and Forecasts (2020-2031)
1.5 Global Biologics for Severe Asthma Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Biologics for Severe Asthma Market Dynamics
2.1 Biologics for Severe Asthma Industry Trends
2.2 Biologics for Severe Asthma Industry Drivers
2.3 Biologics for Severe Asthma Industry Opportunities and Challenges
2.4 Biologics for Severe Asthma Industry Restraints
3 Biologics for Severe Asthma Market by Manufacturers
3.1 Global Biologics for Severe Asthma Revenue by Manufacturers (2020-2025)
3.2 Global Biologics for Severe Asthma Sales by Manufacturers (2020-2025)
3.3 Global Biologics for Severe Asthma Average Sales Price by Manufacturers (2020-2025)
3.4 Global Biologics for Severe Asthma Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Biologics for Severe Asthma Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Biologics for Severe Asthma Manufacturers, Product Type & Application
3.7 Global Biologics for Severe Asthma Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Biologics for Severe Asthma Market CR5 and HHI
3.8.2 Global Top 5 and 10 Biologics for Severe Asthma Players Market Share by Revenue in 2024
3.8.3 2024 Biologics for Severe Asthma Tier 1, Tier 2, and Tier 3
4 Biologics for Severe Asthma Market by Type
4.1 Biologics for Severe Asthma Type Introduction
4.1.1 Omalizumab
4.1.2 Benralizumab
4.1.3 Dupirumab
4.1.4 Mepolizumab
4.1.5 Reslizumab
4.1.6 Tezepelumab-ekko
4.2 Global Biologics for Severe Asthma Sales by Type
4.2.1 Global Biologics for Severe Asthma Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Biologics for Severe Asthma Sales by Type (2020-2031)
4.2.3 Global Biologics for Severe Asthma Sales Market Share by Type (2020-2031)
4.3 Global Biologics for Severe Asthma Revenue by Type
4.3.1 Global Biologics for Severe Asthma Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Biologics for Severe Asthma Revenue by Type (2020-2031)
4.3.3 Global Biologics for Severe Asthma Revenue Market Share by Type (2020-2031)
5 Biologics for Severe Asthma Market by Application
5.1 Biologics for Severe Asthma Application Introduction
5.1.1 Clinic
5.1.2 Hospital
5.1.3 Other
5.2 Global Biologics for Severe Asthma Sales by Application
5.2.1 Global Biologics for Severe Asthma Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Biologics for Severe Asthma Sales by Application (2020-2031)
5.2.3 Global Biologics for Severe Asthma Sales Market Share by Application (2020-2031)
5.3 Global Biologics for Severe Asthma Revenue by Application
5.3.1 Global Biologics for Severe Asthma Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Biologics for Severe Asthma Revenue by Application (2020-2031)
5.3.3 Global Biologics for Severe Asthma Revenue Market Share by Application (2020-2031)
6 Global Biologics for Severe Asthma Sales by Region
6.1 Global Biologics for Severe Asthma Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Biologics for Severe Asthma Sales by Region (2020-2031)
6.2.1 Global Biologics for Severe Asthma Sales by Region (2020-2025)
6.2.2 Global Biologics for Severe Asthma Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Biologics for Severe Asthma Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Biologics for Severe Asthma Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Biologics for Severe Asthma Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Biologics for Severe Asthma Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Biologics for Severe Asthma Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Biologics for Severe Asthma Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Biologics for Severe Asthma Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Biologics for Severe Asthma Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Biologics for Severe Asthma Revenue by Region
7.1 Global Biologics for Severe Asthma Revenue by Region
7.1.1 Global Biologics for Severe Asthma Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Biologics for Severe Asthma Revenue by Region (2020-2025)
7.1.3 Global Biologics for Severe Asthma Revenue by Region (2026-2031)
7.1.4 Global Biologics for Severe Asthma Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Biologics for Severe Asthma Revenue (2020-2031)
7.2.2 North America Biologics for Severe Asthma Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Biologics for Severe Asthma Revenue (2020-2031)
7.3.2 Europe Biologics for Severe Asthma Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Biologics for Severe Asthma Revenue (2020-2031)
7.4.2 Asia-Pacific Biologics for Severe Asthma Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Biologics for Severe Asthma Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Biologics for Severe Asthma Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Teva Pharmaceuticals
8.1.1 Teva Pharmaceuticals Comapny Information
8.1.2 Teva Pharmaceuticals Business Overview
8.1.3 Teva Pharmaceuticals Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Teva Pharmaceuticals Biologics for Severe Asthma Product Portfolio
8.1.5 Teva Pharmaceuticals Recent Developments
8.2 Sanofi
8.2.1 Sanofi Comapny Information
8.2.2 Sanofi Business Overview
8.2.3 Sanofi Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Sanofi Biologics for Severe Asthma Product Portfolio
8.2.5 Sanofi Recent Developments
8.3 Novartis
8.3.1 Novartis Comapny Information
8.3.2 Novartis Business Overview
8.3.3 Novartis Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Novartis Biologics for Severe Asthma Product Portfolio
8.3.5 Novartis Recent Developments
8.4 Roche
8.4.1 Roche Comapny Information
8.4.2 Roche Business Overview
8.4.3 Roche Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Roche Biologics for Severe Asthma Product Portfolio
8.4.5 Roche Recent Developments
8.5 Regeneron Pharmaceuticals
8.5.1 Regeneron Pharmaceuticals Comapny Information
8.5.2 Regeneron Pharmaceuticals Business Overview
8.5.3 Regeneron Pharmaceuticals Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Regeneron Pharmaceuticals Biologics for Severe Asthma Product Portfolio
8.5.5 Regeneron Pharmaceuticals Recent Developments
8.6 GSK
8.6.1 GSK Comapny Information
8.6.2 GSK Business Overview
8.6.3 GSK Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 GSK Biologics for Severe Asthma Product Portfolio
8.6.5 GSK Recent Developments
8.7 AstraZeneca
8.7.1 AstraZeneca Comapny Information
8.7.2 AstraZeneca Business Overview
8.7.3 AstraZeneca Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 AstraZeneca Biologics for Severe Asthma Product Portfolio
8.7.5 AstraZeneca Recent Developments
8.8 Amgen
8.8.1 Amgen Comapny Information
8.8.2 Amgen Business Overview
8.8.3 Amgen Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Amgen Biologics for Severe Asthma Product Portfolio
8.8.5 Amgen Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Biologics for Severe Asthma Value Chain Analysis
9.1.1 Biologics for Severe Asthma Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Biologics for Severe Asthma Production Mode & Process
9.2 Biologics for Severe Asthma Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Biologics for Severe Asthma Distributors
9.2.3 Biologics for Severe Asthma Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.